Chen B, Nelin VE, Locy ML, Jin Y, Tipple TE. Thioredoxin-1 mediates hypoxia-induced pulmonary artery smooth muscle cell proliferation. Am J Physiol Lung Cell Mol Physiol 305: L389-L395, 2013. First published June 28, 2013 doi:10.1152/ajplung.00432.2012.-Pathological pulmonary artery smooth muscle cell (PASMC) proliferation contributes to pulmonary vascular remodeling in pulmonary hypertensive diseases associated with hypoxia. Both the hypoxia-inducible factor (HIF) and phosphatidylinositol 3-kinase (PI3K)/serine/threonine kinase (Akt) pathways have been implicated in hypoxia-induced PASMC proliferation. Thioredoxin-1 (Trx1) is a ubiquitously expressed protein that is involved in redox-dependent signaling via HIF and PI3K-Akt in cancer. The role of Trx1 in PASMC proliferation has not been elucidated. The present studies tested the hypothesis that Trx1 regulates hypoxia-induced PASMC proliferation via HIF and/or PI3K-and Akt-dependent mechanisms. Following exposure to chronic hypoxia, our data indicate that Trx1 activity is increased in adult murine lungs. Furthermore, hypoxia-induced increases in cellular proliferation are correlated with increased Trx1 expression, HIF activation, and Akt activation in cultured human PASMC. Both small-interfering RNA-mediated knockdown and pharmacological Trx1 inhibition attenuated hypoxia-induced PASMC proliferation, HIF activation, and Akt activation. While Trx1 knockdown suppressed hypoxia-induced PI3K-Akt activation in PASMC, PI3K-Akt inhibition prevented hypoxia-induced proliferation but had no effect on hypoxia-induced increases in Trx1 or HIF activation. Thus, our findings indicate that Trx1 contributes to hypoxia-induced PASMC proliferation by modulating HIF activation and subsequent PI3K-Akt activation. These novel data suggest that Trx1 might represent a novel therapeutic target to prevent hypoxic PASMC proliferation. pulmonary hypertension; hypoxia-inducible factor; phosphatidylinositol 3-kinase; serine/threonine kinase
PULMONARY ARTERIAL HYPERTENSION (PAH) is a life-threatening complication of chronic hypoxic lung diseases. Enhanced pulmonary artery smooth muscle cell (PASMC) proliferation significantly contributes to vascular remodeling in hypoxiaassociated PAH (16) . The signaling pathways responsible for pathological PASMC proliferation in hypoxic lung diseases are incompletely understood. Thus, the identification of key regulators of hypoxic PASMC proliferation could yield potential therapeutic targets.
Thioredoxin (Trx), a ubiquitously expressed redox protein with a conserved active site, acts as the major cellular protein disulfide reductase (15) . The Trx system also includes thioredoxin reductase (TrxR), which regenerates active Trx by reducing oxidized Trx from a disulfide to a dithiol using NADPH as the electron donor. Trx and TrxR are present in distinct isoforms that are predominantly cytosolic (Trx1 or TrxR1) or mitochondrial (Trx2 and TrxR2), and genetic deletion of any of these isoforms is embryonically lethal (8, 20, 26, 29) . Trx1 acts as a redox-dependent transcription factor for hypoxia-inducible factor (HIF)-1␣. HIF signaling is strongly implicated in the pathogenesis of PAH (3, 28, 40, 45, 46) . Oxidative stress induced by hypoxia, ionizing radiation, or H 2 O 2 causes nuclear accumulation of Trx1 (13, 44) . In the nucleus, Trx1 acts as a redox-dependent transcription factor to promote HIF signaling (3, 28, 45) . Trx1 overexpression increases HIF activation in cancer cells and increases proliferation of cancer and aortic smooth muscle cells (SMCs) (36, 45) .
Hypoxia initiates phosphatidylinositol 3-kinase (PI3K) signaling leading to serine/threonine kinase (Akt) phosphorylation. PI3K-Akt activation plays a critical role in cellular growth, proliferation, migration, and survival (19) . PI3K-Akt may play a critical role in hypoxia-induced cell proliferation, since activated Akt has been demonstrated in vascular remodeling and SMC proliferation following vascular injury (19) . Trx1 has been linked to Akt-dependent signaling in some cell types (27) .
Although the role of Trx1 in HIF signaling and tumorigenesis is well established, little is known regarding the contribution of Trx1 toward hypoxia-induced PASMC proliferation. We have previously shown that hypoxia induces human PASMC (hPASMC) proliferation in vitro (5, 6 ). The present studies tested the hypothesis that Trx1 regulates PASMC proliferation via HIF and/or PI3K-and Akt-dependent mechanisms.
MATERIALS AND METHODS
Animal model. All animals received humane care in accordance with the guidelines of the National Institutes of Health. The study protocol was approved by the Institutional Animal Care and Use Committee of the Research Institute at Nationwide Children's Hospital. Age-matched adult C57Bl/6 mice were placed in room air (normoxia) or 10% oxygen (hypoxia) in a Plexiglas chamber with a constant flow of nitrogen at 1-3 l/min for 4 wk. Following the exposure time, the mice were killed using pentobarbital, and the lungs were collected.
Tissue preparation. At the end of the study period, the mice were killed with an intraperitoneal injection of pentobarbital (100 mg/kg). The lungs were removed, weighed, freeze-clamped in liquid nitrogen, and kept at Ϫ80°C. The organs were homogenized in 0.8 ml of ice-cold Dulbecco's PBS (pH 7.4) as previously described (7) . Samples were centrifuged at 12,000 g for 15 min, and the supernatants were collected and analyzed for total protein content using the Bradford assay (Bio-Rad, Hercules, CA). The supernatants were stored at Ϫ80°C for further study.
Trx activity. Trx1 activities in lung tissue homogenates were determined as previously described (4, 32) with TrxR1 substituted for Trx1 in the reaction mixture.
Cell culture and treatments. hPASMC (Lonza, Walkersville, MD) were cultured in smooth muscle growth media with growth factors (SmGM-2; Lonza) at 37°C (21% O 2, 5% CO2, and balance N2). Cells between the fifth and eighth passages from two donors were used for experiments, grown to ϳ80 -90% confluence, and then incubated in normoxia (21% O 2, 5% CO2, balance N2) or hypoxia (1% O2, 5% CO 2, balance N2) as described.
Protein isolation. Protein was isolated from hPASMC as previously described (5) . Briefly, hPASMC were washed with PBS, and protein was harvested in ice-cold lysis buffer containing 20 mM HEPES (pH 7.4), 50 mM ␤-glycerophosphate, 2 mM EGTA, 1 mM DTT, 10 mM NaF, 1 mM Na 3VO4, 1% Triton X-100, 10% glycerol, 2 M leupeptin, 2 M aprotinin, and 1 mM phenylmethylsulfonyl fluoride. Samples were centrifuged at 12,000 g for 15 min, and the supernatants were stored at Ϫ80°C. Total protein contents were determined by Bradford assay (Bio-Rad).
Western blot analysis. Equal amounts of protein were diluted with SDS sample buffer (Invitrogen, Carlsbad, CA), heated to 95°C for 5 min, and centrifuged at 10,000 g at room temperature for 2 min. The proteins were transferred to polyvinylidene difluoride membranes and blocked using Tris-buffered saline with 0.1% Tween (pH 7.6) containing 5% nonfat dried milk at room temperature for 1 h. Membranes were then incubated with rabbit anti-human Trx1 (1:1,000; Cell Signaling), rabbit anti-human phospho-Akt (1:1,000; Cell Signaling), or rabbit anti-human Akt (1:1,000; Cell Signaling) primary antibody overnight at 4°C followed by incubation with horseradish peroxidaseconjugated goat anti-rabbit IgG (1:15,000; Bio-Rad) secondary antibody for 1 h. Bands were visualized using enhanced chemiluminescence (GE Healthcare, Piscataway, NJ). To control for protein loading, membranes were stripped and reprobed for ␤-actin (1:5,000; Sigma-Aldrich, St. Louis, MO). The relative densities of the bands of interest were quantified using TotalLab TL120 software (TotalLab, Durham, NC).
Trx1 small-interfering RNA treatment. hPASMC were seeded at equal densities in six-well plates and were cultured in normoxia and grown to 80% confluence before transfection with 50 nM Trx1 small-interfering RNA (siRNA; Thermo Fisher, Lafayette, CO) or scramble siRNA control using DharmaFECT transfection reagent (Thermo Fisher) according to the manufacturer's protocol. After 24 h, the transfection media was removed, cells were washed, and smooth muscle growth media were added. Cells were then incubated in normoxia or hypoxia and were collected in lysis buffer as previously described.
Trx1 or PI3K-Akt inhibition. hPASMC were seeded at equal densities in six-well plates and grown to 80 -90% confluence in normoxia. For Trx1 inhibition, PX-12 (Tocris, Minneapolis, MN) diluted in DMSO was added to the culture media (2 M final concentration). For PI3K-Akt inhibition, LY-294002 (Cell Signaling, Danvers, MA) diluted in DMSO was added to the culture media (10 M final concentration). Control cells received an equal volume of DMSO. Cells were then incubated in normoxia or hypoxia and were collected in lysis buffer as previously described.
Cell viability. To determine viable cell numbers, Trx1-specific siRNA-transfected, LY-294002-treated, or PX-12-treated hPASMC and their respective controls were seeded in six-well plates at a density of 10,000 cells/well and were incubated in normoxia or hypoxia for 120 h. Viable cell numbers were counted using a hemocytometer and trypan blue exclusion as previously described (5, 43) .
Dual-luciferase activity assay. A hypoxia response element (HRE) promoter plasmid consisting of a trimer of murine Epo 3=-enhancer fused to a luciferase reporter was a gift from Dr. Paul Schumacker (Northwestern University). hPASMC were cotransfected at 90% confluence with HRE-luciferase or empty vector control plasmid DNA and Renilla luciferase (Promega, Madison, WI) internal control vector plasmid DNA using Lipofectamine2000 transfection reagent (Invitrogen). Twenty-four hours after transfection, cells were maintained in either normoxia or were cultured in hypoxia for 24 h before being harvested. Luciferase activities in cell lysates were determined using the Dual-Luciferase Reporter Assay System (Promega) and a Veritas Microplate Luminometer (Promega). Firefly luciferase was normalized to Renilla luciferase, and the normalized activity of the treatment groups was further normalized to that of the control group.
Statistics. Data, expressed as means Ϯ SE, were analyzed by using unpaired t-test, one-way ANOVA followed by Newman-Keuls post hoc testing, or two-way ANOVA. Two-way ANOVA was used with treatment and oxygen exposure as independent variables followed by Neuman-Kuels or Tukey post hoc testing for individual differences (GraphPad Prism, La Jolla, CA). Significance was accepted at P Ͻ 0.05.
RESULTS
Lung Trx1 activity is increased in lungs from adult mice exposed to chronic hypoxia. Chronic hypoxic exposure is a well-established animal model for pulmonary hypertension (14) . To evaluate the impact of hypoxia on pulmonary Trx1, we determined Trx1 activity in lung homogenates obtained from adult mice exposed to normobaric hypoxia (10% O 2 ) or normoxia for 4 wk. Lung Trx1 activities in lungs from hypoxia-exposed mice were two times greater than in lungs from normoxic controls ( Fig. 1) .
Hypoxia increases Trx1 expression in hPASMCs. To determine the impact of chronic hypoxia on Trx1 expression in PASMC, we performed Western blot analyses on lysates from hPASMC exposed to normoxia or hypoxia (1% O 2 ) for 24, 48, or 72 h. In normoxia, Trx1 protein levels at 24, 48, or 72 h were not different (Fig. 2) . In contrast, Trx1 protein levels in hypoxia-exposed hPASMCs were 49% greater at 48 h and 65% greater at 72 h than in corresponding normoxia-exposed control cells (Fig. 2) . No effects of exposure or time on hPASMC TrxR1, Trx2, or TrxR2 protein levels were detected (data not shown).
Trx1 knockdown prevents hypoxia-induced hPASMC proliferation. To test the hypothesis that Trx1 regulates hypoxiainduced hPASMC proliferation, we used RNA interference to decrease Trx1 expression. hPASMC were treated with Trx1-specific siRNA or scramble siRNA for 24 h and were then exposed to normoxia or hypoxia for 48 h. To verify knockdown, Trx1 expression in cell lysates was determined by Western blot. Transfection of hPASMCs with Trx1-specific siRNA robustly decreased Trx1 expression in both normoxia and hypoxia compared with scramble siRNA-transfected cells (Fig. 3A) .
To determine the contribution of Trx1 toward hypoxiainduced PASMC proliferation, transfected Trx1-specific or scramble siRNA hPASMC were seeded at equal densities (10,000 cells/well) and were then exposed to normoxia or hypoxia for 120 h. At the conclusion of the exposure period, viable cell numbers were determined using trypan blue exclusion. Consistent with previous results (5, 6), hypoxic exposure increased viable hPASMC numbers (Fig. 3B ). Trx1-specific siRNA treatment completely prevented hypoxia-induced increases in viable cell numbers (Fig. 3B) . Furthermore, in normoxia-exposed cells, Trx1-specific siRNA treatment also decreased viable cell numbers compared with normoxic scramble siRNA-treated hPASMC (Fig. 3B) .
Pharmacological Trx1 inhibition prevents hypoxia-induced hPASMC proliferation. The small molecule Trx1 inhibitor PX-12 was used to further investigate the role of Trx1 in hypoxia-induced PASMC proliferation. hPASMCs were seeded at equal densities (10,000 cells/well), and PX-12 (2 M) or vehicle was added to the medium. The cells were incubated for 120 h in normoxia or hypoxia, and viable cell numbers were determined using trypan blue exclusion. Hypoxic exposure significantly increased viable cell numbers while with PX-12 treatment completely prevented hypoxiainduced increases in viable cell numbers (Fig. 3C) . The effect of PX-12 treatment on viable cell numbers was not restricted to hypoxia alone. PX-12 also decreased viable cell numbers compared with vehicle-treated cells exposed to normoxia (Fig. 3C) .
Trx1 knockdown decreases HIF activation. To test the hypothesis that siRNA-mediated Trx1 knockdown decreases HIF-mediated signaling in hPASMCs, we used HRE-luciferase activity as a surrogate for HIF trans-activation. hPASMCs were cotransfected for 24 h with either Trx1-specific siRNA or scramble siRNA in combination with HRE-luciferase reporter and Renilla-luciferase plasmid DNA. Following exposure to normoxia or hypoxia for an additional 24 h, luciferase activity was measured in cellular homogenates. In scramble siRNAtreated cells, hypoxic exposure increased HRE-luciferase activity by ϳ3.5-fold (Fig. 4A) . Consistent with our hypothesis, treatment with Trx1-specific siRNA significantly attenuated hypoxia-induced increases in HRE-luciferase activity (Fig.  4A ). Trx1 knockdown appeared to decrease HRE-luciferase activity in normoxia-exposed cells compared with scramble 
Control
Scramble siRNA Trx1 siRNA Fig. 3 . Trx1 knockdown or Trx1 inhibition prevents hypoxia-induced hPASMC proliferation. hPASMCs were treated with Trx1-specific small-interfering RNA (siRNA) or scramble siRNA control as described in MATERIALS AND METHODS. A: validation of Trx1 knockdown in hPASMC following siRNA treatment and exposure to normoxia or hypoxia for 48 h. B: hPASMCs were treated with Trx1-specific siRNA or scramble siRNA control as described in MATERIALS AND METHODS and were then seeded at equal densities (10,000 cells/well). Cells were then exposed to normoxia or hypoxia for 120 h, and viable cells were counted. Analyses indicated independent effects of exposure and treatment but no interaction. C: hPASMCs were seeded at equal densities (10,000 cells/well) and were treated with 2 M PX-12 in DMSO or vehicle alone as described in MATERIALS AND METHODS. Cells were then exposed to normoxia or hypoxia for 120 h, and viable cells were counted. Data are presented as percentage of seeded cells. Analyses indicated independent effects of exposure and treatment but no interaction. *Different from normoxia control, P Ͻ 0.001; #different from hypoxia, same treatment, P Ͻ 0.05 (n ϭ 6).
siRNA-treated control cells although the differences were not statistically significant by the methods used (Fig. 4A) . Pharmacological Trx1 inhibition decreases HIF activation. PX-12 treatment was used as an alternative approach to examine the role of Trx1 in hypoxia-induced HIF trans-activation. hPASMCs were cotransfected with HRE-luciferase reporter and Renilla-luciferase plasmid DNA for 24 h and were then exposed to normoxia or hypoxia for 24 h in the presence of PX-12 (2 M) or vehicle. Again, hypoxic exposure robustly increased HRE-luciferase activity (Fig. 4B) . Hypoxia-induced increases in HRE-luciferase activity were significantly attenuated in PX-12-treated cells (Fig. 4B) . PX-12 treatment also significantly decreased HRE-luciferase activity in normoxic cells compared with DMSO-treated controls (Fig. 4B) .
Trx1 knockdown prevents hypoxia-induced Akt phosphorylation. Akt activation is implicated in hypoxia-induced hPASMC proliferation (18) . To confirm Akt activation in our model, we used Western blot analyses to assess phospho-Akt levels in hPASMCs following incubation in normoxia or hypoxia. To determine the role of Trx1 in hypoxia-induced Akt activation, we examined the effect of Trx1 knockdown on Akt phosphorylation. hPASMCs were transfected with Trx1-specific or scramble siRNA for 24 h and were subsequently exposed to normoxia or hypoxia for 24 h. Hypoxia induced Akt phosphorylation in scramble siRNA-treated hPASMCs. Trx1 knockdown completely attenuated hypoxia-induced increases in Akt phosphorylation (Fig. 5A) . In normoxia, Trx1 knockdown increased Akt phosphorylation relative to scramble siRNAtreated controls (Fig. 5A) .
PI3K-Akt inhibition prevents hypoxia-induced hPASMC proliferation but not hypoxia-induced increases in Trx1 levels.
The pharmacological Akt inhibitor LY-294002 was used to determine the effect of Akt activation on hPASMC proliferation. hPASMCs were seeded at equal densities (10,000 cells/ well), and LY-294002 (10 M) or vehicle was added to the medium. The cells were then incubated for 120 h in normoxia or hypoxia, and viable cell numbers were determined using trypan blue exclusion. LY-294002 treatment completely prevented hypoxia-induced increases in viable cell numbers and also decreased viable cell numbers in normoxia (Fig. 5B) .
To determine the effect of PI3K-Akt inhibition on Trx1 expression, hPASMCs were treated with LY-294002 (10 M) or vehicle for 48 h. As demonstrated in Fig. 1 , Trx1 expression was increased by hypoxic exposure (Fig. 5C ). In hypoxia, Trx1 expression was not different between LY-294002-treated and vehicle-treated cells (Fig. 5C ). Conversely, LY-294002 treatment significantly increased Trx1 levels in normoxia compared with vehicle-treated control cells (Fig. 5C) .
PI3K-Akt inhibition has no effect on hypoxia-induced HIF trans-activation. To establish the relationship between hypoxia-induced PI3K-Akt activation and HIF trans-activation,
hPASMCs were cotransfected with HRE-luciferase reporter and Renilla-luciferase plasmid DNA for 24 h. Cells were then exposed to normoxia or hypoxia for 24 h in the presence of LY-294002 (10 M) or vehicle. LY-294002 treatment had no effect on hypoxia-induced increases in HRE-luciferase activity (Fig. 5D ).
DISCUSSION
The major findings of these studies are: 1) lung Trx1 activity is increased in adult mice exposed to chronic hypoxia; 2) hypoxia increases Trx1 expression, proliferation, and HIF trans-activation in hPASMC; 3) both Trx1 knockdown and pharmacological Trx1 inhibition prevent hypoxia-induced hPASMC proliferation and attenuate HIF trans-activation; 4) Trx1 knockdown prevents hypoxia-induced Akt phosphorylation in hPASMC; and 5) PI3K-Akt inhibition in hPASMC prevents hypoxiainduced proliferation but not hypoxia-induced increases in Trx1 levels or HIF trans-activation. These novel data indicate that Trx1 regulates hypoxia-induced PASMC proliferation via HIF-dependent mechanisms with downstream effects on PI3K-Akt signaling.
Trx1 has previously been shown to contribute toward proliferative responses in other SMC types, although the results vary depending on the cell type and conditions studied. Rat vascular SMC proliferation was associated with a reduction in Trx1 expression, whereas Trx1 knockdown enhanced SMC proliferation (41) . In human vascular SMC, Trx1 activity and expression were increased and cell growth was inhibited following endothelial cell coculture (47) . Furthermore, recombinant Trx1 treatment or transgenic Trx1 overexpression inhibited airway SMC remodeling in a murine asthma model (17) . In contrast to the above reports, our data indicate that Trx1 promotes PASMC proliferation, which is consistent with pre- A: hPASMCs were cotransfected with Trx1-specific siRNA or scramble siRNA control in combination with HRE-luciferase reporter and Renilla-luciferase plasmid DNA as described in MATERIALS AND METHODS and were exposed to normoxia or hypoxia for 24 h. HRE-luciferase activity was measured. Analyses indicated independent effects of exposure and treatment but no interaction. B: hPASMCs were cotransfected with HRE-luciferase reporter and Renilla-luciferase plasmid DNA, were treated with 2 M PX-12 in DMSO or vehicle alone as described in MATERIALS AND METHODS, and were exposed to normoxia or hypoxia for 24 h. Analyses indicated independent effects of treatment and exposure but no interaction. *Different from normoxia control, P Ͻ 0.001; #different from hypoxia control, P Ͻ 0.05 (n ϭ 5).
viously reported findings in human SMC (36) . Thus, the variability in SMC-specific proliferative responses to Trx1 suggests the need for caution with extrapolating findings between SMCs of different origins. Given our finding of increased Trx1 activity in the lungs from mice exposed to chronic hypoxia (Fig. 1) , we used hPASMC to determine the contribution of Trx1 toward PASMC proliferation. Our data indicate that hypoxia increased Trx1 expression in hPASMCs (Fig. 2) . Both siRNA-mediated Trx1 knockdown (Fig. 3B ) and pharmacological Trx1 inhibition (Fig. 3C) prevented hypoxia-induced PASMC proliferation. Intriguingly, both siRNA-mediated knockdown and pharmacological inhibition of Trx1 also attenuated hPASMC proliferation in normoxia. Collectively, our data suggest that Trx1 significantly contributes to both basal and hypoxia-induced PASMC proliferation.
Alveolar hypoxia prevents HIF-1␣ degradation and promotes HIF trans-activation. The subsequent upregulation of Fig. 5 . Trx1 knockdown prevents hypoxia-induced serine/threonine kinase (Akt) phosphorylation while phosphatidylinositol 3-kinase (PI3K)-Akt inhibition prevents hypoxia-induced hPASMC proliferation. PI3K-Akt inhibition has no effect on hypoxia-induced increases in Trx1 expression or HRE-luciferase activity. hPASMCs were treated with Trx1-specific siRNA or scramble siRNA control as described in MATERIALS AND METHODS and were exposed to normoxia or hypoxia for 24 h. A: representative Western blots for phospho-Akt (pAkt), total Akt, and ␤-actin are shown. Data are presented as fold change Ϯ SE relative to total Akt. Analyses indicated an interaction between exposure and treatment. *Different from normoxia, scramble siRNA, P Ͻ 0.05; #different from hypoxia, scramble siRNA, P Ͻ 0.05 (n ϭ 6). B: hPASMCs were seeded at equal densities (10,000 cells/well), treated with 10 M LY-294002 in DMSO or vehicle alone as described in MATERIALS AND METHODS. Following exposure to normoxia or hypoxia for 120 h, viable cells were counted. Data are presented as percentage of seeded cells. Analyses indicated independent effects of and an interaction between treatment and exposure. *Different from normoxia, vehicle-treated, P Ͻ 0.001; #different from hypoxia, vehicle-treated, P Ͻ 0.001 (n ϭ 6). C: hPASMCs were treated with 10 M LY-294002 in DMSO or vehicle alone as described in MATERIALS AND METHODS and were exposed to normoxia or hypoxia for 48 h. Representative Western blots for Trx1 and ␤-actin are shown. Data are presented as fold change Ϯ SE relative to ␤-actin. Analyses indicated an independent effect of treatment. *Different from normoxia, vehicle-treated, P Ͻ 0.05 (n ϭ 3). D: hPASMCs were cotransfected with HRE-luciferase reporter and Renilla-luciferase plasmid DNA, treated with 10 M LY-294002 in DMSO or vehicle alone as described in MATERIALS AND METHODS, and were exposed to normoxia or hypoxia for 24 h. Analyses indicated an independent effect of exposure. *Different from normoxia, same treatment, P Ͻ 0.001 (n ϭ 5).
HIF target genes has been implicated to play a role in the development PAH associated with hypoxia (37) (38) (39) . Hypoxia causes nuclear Trx1 accumulation (13, 44) . In the nucleus, Trx1 regulates the activation of multiple transcription factors, including HIF-1 (9, 13, 28) . In hypoxia-exposed human breast carcinoma cells, Trx1 overexpression increases HIF transactivation and increases HIF-1␣ levels (45) . Furthermore, antisense Trx1 treatment prevents nuclear translocation of HIF-1␣ (21) . Our data clearly indicate that both Trx1 knockdown (Fig. 4A ) and Trx1 inhibition (Fig. 4B ) attenuated hypoxia-induced increases in HIF trans-activation. Basal HIF trans-activation in normoxia was also affected by Trx1 inhibition. Despite basal decreases in HIF trans-activation in hPASMC treated with either Trx1-specific siRNA or PX-12, HRE-luciferase activity in treated cells was still increased by hypoxia. These findings suggest the presence of Trx1-independent hypoxia-induced proliferative mechanisms in hPASMC. Nonetheless, our data clearly illustrate that Trx1 significantly contributes to hypoxiainduced HIF signaling in hPASMC. Increased PI3K activity leads to Akt phosphorylation and cell proliferation (25) . Previous studies have indicated that hypoxia-induced increases in HIF trans-activation in the pulmonary vasculature precede Akt phosphorylation and PASMC proliferation (19, 34) . Phosphatase and tensin homolog (PTEN) is a negative regulator of PI3K-Akt activation. In hypoxia, PTEN overexpression has been demonstrated to block Akt phosphorylation and prevent rat PASMC proliferation (24) . Our data indicate that Trx1 is required for hypoxia-induced Akt activation in hPASMC, since Trx1 knockdown prevented hypoxia-induced Akt phosphorylation (Fig. 5A) . Although Akt inhibition prevented hypoxia-induced hPASMC proliferation, it had no effect on hypoxia-induced increases in Trx1 expression (Fig. 5C ) or HIF trans-activation (Fig. 5D) . Collectively, our findings suggest that, in hypoxia, Trx1 contributes to hPASMC proliferation via HIF transactivation with subsequent effects on PI3K-Akt signaling (Fig. 6) .
In normoxia, Trx1 knockdown increased Akt phosphorylation (Fig. 5A ) but decreased proliferation (Fig. 3B) . Decreased Trx1 expression was also associated with enhanced Akt phosphorylation in aortic SMC; however, proliferation was increased (41) . Reversible oxidation/reduction is an important regulatory mechanism for PTEN function (22) . Trx1 regulates PTEN function by serving as the preferential electron donor to reduce oxidized (inactive) PTEN (22) . We speculate that, in normoxia, Trx1 knockdown alters the redox status of PTEN, resulting in diminished PTEN function and enhanced Akt phosphorylation. Trx1 is also a preferential electron donor for ribonucleotide reductase, which is required to provide deoxyribonucleotides for DNA synthesis (2, 30) . Impaired DNA synthesis following Trx1 knockdown is a possible explanation for decreased hPASMC proliferation in both normoxia and hypoxia. Nonetheless, our data suggest that the contribution of Trx1 toward PI3K-Akt activation is likely to be dependent on O 2 tension. In hypoxia, we speculate that the contribution of Trx1 toward HIF-dependent proliferation is greater than its effect on the PI3K-Akt pathway. Furthermore, our finding of enhanced Trx1 expression following PI3K-Akt inhibition in normoxia suggests the presence of additional cross talk between Trx1 and the PI3K-Akt pathways in hPASMC. Further studies to address the influence of O 2 tension on the relationship between Trx1 and PI3K-Akt signaling in PASMC are necessary; however, such investigations are beyond the scope of the present manuscript.
There are additional limitations to the present studies that should be noted. Pathological PASMC proliferation occurs in resistance level pulmonary arteries in pulmonary hypertensive diseases associated with chronic hypoxia. The hPASMC used in our studies were isolated from main pulmonary artery segments. Although the present studies identify a novel role for Trx1 in the regulation of hypoxia-induced PASMC proliferation, the role of Trx1 in hypoxia-induced resistance level PASMC proliferation will need to be validated. Second, 1% O 2 represents an extreme level of hypoxia. We chose to use 1% O 2 because we have found that this level of hypoxia reliably and reproducibly induces hPASMC proliferation in our cell culture system (5, 6) . Finally, Trx1 is ubiquitously expressed in all cell types. Thus, undesirable effects of Trx1 inhibition in other cells or tissues might limit the clinical utility of Trx1 inhibition. We have previously reported that Trx system disruption in vivo and in vitro is detrimental only upon simultaneous glutathione (GSH) system disruption (23, 42) . Cross talk between the Trx and GSH systems most reasonably explains the tolerance of Trx system disruption inhibition in vivo and in vitro (1, 23, 31, 33, 35, 42) . GSH system deficiencies, other than in dietary riboflavin deficiency, are virtually unknown in humans (10 -12) .
In conclusion, our data indicate that Trx1 regulates hypoxiainduced PASMC proliferation. Our findings are consistent with a model in which Trx1 regulates hypoxia-induced PASMC proliferation via HIF and PI3K-Akt signaling pathways (Fig.  6) . We speculate that Trx1 may represent a novel therapeutic target to prevent aberrant PASMC proliferation, a feature of pulmonary vascular remodeling in pulmonary hypertensive diseases associated with hypoxia.
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